ImmunoGenesis is a Houston, Texas-based company developing novel drugs with technology spun out of MD Anderson Cancer Center (MDACC). In the last decade, immunotherapy drugs, called checkpoint inhibitors, have revolutionized therapy for many cancers, and new combination therapies continue to evolve. However, only a minority (~45%) of cancer patients are eligible to receive these drugs and among those less than 20% achieve a complete or even partial response. ImmunoGenesis' IMGS-001 is a new type of immunotherapy that for the first time can both benefit the majority (55%) of patients ineligible to receive current drugs, and also has the potential to improve responses in existing indications. ...

Read More

ImmunoGenesis is a Houston, Texas-based company developing novel drugs with technology spun out of MD Anderson Cancer Center (MDACC). In the last decade, immunotherapy drugs, called checkpoint inhibitors, have revolutionized therapy for many cancers, and new combination therapies continue to evolve. However, only a minority (~45%) of cancer patients are eligible to receive these drugs and among those less than 20% achieve a complete or even partial response. ImmunoGenesis' IMGS-001 is a new type of immunotherapy that for the first time can both benefit the majority (55%) of patients ineligible to receive current drugs, and also has the potential to improve responses in existing indications. In pre-clinical studies, IMGS-001 out-performed the most potent existing drug in freeing the immune system to reject established cancers. In this CPRIT Product Development Grant application, ImmunoGenesis will take its innovative, first-in-class immunotherapy drug, IMGS-001, to the FDA to request approval to open a clinical trial at MDACC and other Texas clinics. The company is also developing a biomarker test to identify the patients most likely to benefit from IMGS-001.

Read Less